Home›Research›Compare›TB-500 vs Teduglutide
Peptide ComparisonTB-500 vs Teduglutide
Both are Tissue Repair peptides.
TB-500
thymosin beta 4
Half-life: 5–7 days
402 providers listed
Teduglutide
Gattex
Half-life: ~2 hours
No providers listed yet
Teduglutide is FDA-approved, while TB-500 is banned from compounding — the clearest structural difference between them.
TB-500
Evidence
Half-life
5–7 days
Teduglutide
Evidence
Half-life
~2 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Teduglutide |
| Further along in FDA review | Teduglutide |
| Less frequent dosing (longer half-life) | TB-500 |
| More provider options (402 vs 0) | TB-500 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
TB-500
Teduglutide
TB-500
Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…
Teduglutide
From childhood to adulthood in chronic intestinal failure: A nationwide study.
A Long-Acting Glucagon-like Peptide 2 Protracted by Coomassie Brilliant Blue to Enhance Intestinal Growth in…
PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.
Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?
+5 more
About TB-500
TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.
About Teduglutide
GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
TB-500
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
global — WADA
TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.
sourceTeduglutide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
TB-500
BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
TB-500
Teduglutide
Not enough vendor pricing yet.
Where to source these peptides
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). TB-500 vs Teduglutide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/tb-500/teduglutide